The market has moved up so much and so fast. I think there is too much FOMO and not much value left in the market. Maybe it’s wiser to step aside and stay defensive.
🇺🇸🇭🇰🇸🇬 Big moves across US, HK, SG markets. Join the chat & earn Task Coins!
IMPACT Therapeutics, Inc., a biotechnology company, researches and develops synthetic lethality (SL)-based precision anti-cancer therapies in China and internat...
Impact Therapeutics (7630.HK) opened at HK$9.97, slid to HK$8.955 by 10:20 BJ, rebounded to HK$9.80 in the afternoon and closed at HK$9.325, up 2.3% from the prior HK$9.115 close, as a board-authorised buyback of up to HK$100 million combined with Q2 2026 revenue of HK$60.75 million (+339% YoY) and a net loss narrowed 25.6% to HK$52.44 million supported the tape. The company remains loss-making, with a -86.3% net margin and EPS of -HK$0.2132, and trades at 2.95x book. The shares sit below the MA20 of HK$9.563 and MA60 of HK$12.299, down 77.72% year-to-date and 80.56% below the May 14 52-week high of HK$47.98, though still 20.56% above the November 1 low of HK$7.735. A cornerstone lock-up expiry that previously triggered a 7% single-day drop remains the counterweight to the buyback.
The stock opened 0.28 HKD lower and trended up through the session, closing +8.64% at 9.115 HKD after lifting from an 8.13 HKD intraday low to 9.245 HKD on 78.6 million HKD of turnover and a 3.16% turnover rate; the direct trigger was the board's authorization of a buyback of up to HK$100 million, which followed last week's buyback-driven 9.59% rebound and kept buying interest alive. Q2 revenue of 60.75 million HKD rose 339.37% year on year, while the net loss of 52.44 million HKD narrowed 25.64% and the per-share loss of 0.2132 HKD improved 32.64%, still leaving the company unprofitable at a -8.67 PE. On price location, the 9.115 HKD close remains below the MA20 of 9.747 and the MA60 of 12.346, down 78.23% year to date, 81% below the 47.98 HKD 52-week high and only 17.8% above the 7.735 HKD low. Though an approaching cornerstone lockup expiry previously triggered a single-day 7% drop.
Impact Therapeutics-B reversed early gains, opening at HK$9.605, which was also the intraday high, then sliding one-way to HK$8.615 at 15:53 in the afternoon session and closing at HK$8.635, down 7.35% from the prior close of HK$9.320 on a 1.12% turnover rate. The move unwound part of the prior session's 9.59% rebound that followed board authorization to buy back up to HK$100 million of shares, while investors also weighed an upcoming cornerstone lockup expiry. Q2 2026 revenue of HK$60.7 million grew 339.37% year on year and the net loss narrowed 25.64% to HK$52.4 million, though the net margin remains -86.33%. The stock is down 79.37% year to date and 82% below its May 14 52-week high of HK$47.98; while 11.64% above the November 1 low of HK$7.735, it still trades under its MA20 of HK$10.185 and MA60 of HK$12.478. The buyback mandate and narrowing losses offer some cushion, though.
Shares reversed an early dip to close up 4.8% at HK$9.465, extending the prior session's roughly 9% rebound after the board authorized an on-market repurchase of up to HK$100 million; the stock slid to HK$9.000 at 09:31 BJ, spiked to HK$9.645 at 13:10 BJ in the afternoon session, then gave back part of the gain on 4.565 million shares worth HK$42.6 million, a 1.7% turnover rate. Q2 2026 revenue reached HK$60.75 million, up 339% year on year, while the HK$52.44 million net loss narrowed 25.6% and loss per share of HK$0.2132 improved 32.6%; net margin stayed at -86.3% and ROE at -23.4%, leaving PE negative and PB at 2.99x on a HK$2.67 billion market cap. The stock remains down 77.4% year to date and 80.3% below its 52-week high of HK$47.98, trading under its MA20 of HK$10.52 and MA60 of HK$12.62, though 22.4% above the November 1 low of HK$7.735. An upcoming cornerstone lockup expiry, which previously preceded a 7% single-day drop, remains a supply overhang.
Impact Therapeutics-B closed at HK$9.03, up 0.17%, in a gap-up that faded: it opened at HK$8.385, spiked to HK$9.91 by 09:36 BJ and then gave most of it back to settle near HK$9.08. The trigger was a board-authorised on-market buyback of up to HK$100 million, which pushed the open more than 11% higher, though a fresh 52-week low of HK$7.735 set on 1 November and the looming expiry of cornerstone investors' lock-up limited follow-through. Fundamentals run the other way: Q2 2026 revenue was HK$60.7 million, up 339.4% year on year, and the net loss narrowed 25.6% to HK$52.4 million, yet the net margin was still -86.3%, with PE -8.59, PB 2.86 and market value HK$2.55 billion. The stock is down 78.4% from HK$41.86 at the start of the year, 81.2% below the HK$47.98 52-week high and still under the MA20 of HK$10.68 and MA60 of HK$12.66, though 10.3 million shares traded and a 3.8% turnover rate point to active dealings near the lows.
The market has moved up so much and so fast. I think there is too much FOMO and not much value left in the market. Maybe it’s wiser to step aside and stay defensive.
🇺🇸🇭🇰🇸🇬 Big moves across US, HK, SG markets. Join the chat & earn Task Coins!
Still waiting for the MAS Equity Market Development Programme to show its fruits of labour. The SG stock market don’t seem to be benefitting that clearly yet.
🇺🇸🇭🇰🇸🇬 Big moves across US, HK, SG markets. Join the chat & earn Task Coins!

🇺🇸🇭🇰🇸🇬 Big moves across US, HK, SG markets. Join the chat & earn Task Coins!
